WO2006056339A1 - A process for the preparation of (s)-(+)-10,11-dihydro-10-hydroxy-5h-dibenz (b,f) azepine-5-carboxyamide - Google Patents
A process for the preparation of (s)-(+)-10,11-dihydro-10-hydroxy-5h-dibenz (b,f) azepine-5-carboxyamide Download PDFInfo
- Publication number
- WO2006056339A1 WO2006056339A1 PCT/EP2005/012205 EP2005012205W WO2006056339A1 WO 2006056339 A1 WO2006056339 A1 WO 2006056339A1 EP 2005012205 W EP2005012205 W EP 2005012205W WO 2006056339 A1 WO2006056339 A1 WO 2006056339A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dibenz
- dihydro
- azepine
- hydroxy
- cyano
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title claims description 7
- ARWDKBAZURSFOU-HNNXBMFYSA-N 2-[(5S)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepin-11-yl]acetamide Chemical compound O[C@H]1CC2=C(N(C3=C1C=CC=C3)CC(=O)N)C=CC=C2 ARWDKBAZURSFOU-HNNXBMFYSA-N 0.000 title abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- QQSMCHOABQHASF-HNNXBMFYSA-N (5s)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carbonitrile Chemical compound O[C@H]1CC2=CC=CC=C2N(C#N)C2=CC=CC=C12 QQSMCHOABQHASF-HNNXBMFYSA-N 0.000 claims abstract description 5
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 claims abstract description 5
- 239000003513 alkali Substances 0.000 claims abstract description 4
- 230000007062 hydrolysis Effects 0.000 claims abstract description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 4
- 125000002560 nitrile group Chemical group 0.000 claims abstract description 3
- 238000000926 separation method Methods 0.000 claims abstract description 3
- 125000000864 peroxy group Chemical group O(O*)* 0.000 claims abstract 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 8
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 claims description 7
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- -1 alicyclic hydrocarbons Chemical class 0.000 claims description 2
- 150000001348 alkyl chlorides Chemical class 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- QQSMCHOABQHASF-UHFFFAOYSA-N 5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carbonitrile Chemical compound OC1CC2=CC=CC=C2N(C#N)C2=CC=CC=C12 QQSMCHOABQHASF-UHFFFAOYSA-N 0.000 abstract description 4
- 125000003368 amide group Chemical group 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LCGTWRLJTMHIQZ-UHFFFAOYSA-N 5H-dibenzo[b,f]azepine Chemical compound C1=CC2=CC=CC=C2NC2=CC=CC=C21 LCGTWRLJTMHIQZ-UHFFFAOYSA-N 0.000 description 1
- LPMHXLQFRXLENP-NRUKRWIHSA-N CCN(COC(c(cccc1)c1C(O[C@H](Cc1c2cccc1)c1ccccc1N2C#N)=O)=O)[C@@H](C)c1ccccc1 Chemical compound CCN(COC(c(cccc1)c1C(O[C@H](Cc1c2cccc1)c1ccccc1N2C#N)=O)=O)[C@@H](C)c1ccccc1 LPMHXLQFRXLENP-NRUKRWIHSA-N 0.000 description 1
- 0 C[C@@](c1ccccc1)NCOC(*1ccccc1C(O[C@@](Cc1c2cccc1)c(cccc1)c1N2C#N)=O)=O Chemical compound C[C@@](c1ccccc1)NCOC(*1ccccc1C(O[C@@](Cc1c2cccc1)c(cccc1)c1N2C#N)=O)=O 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- XZRRVMAQCSEJKI-HNNXBMFYSA-N N#CN(C1=C(C2)C=CCC1)c1ccccc1[C@H]2O Chemical compound N#CN(C1=C(C2)C=CCC1)c1ccccc1[C@H]2O XZRRVMAQCSEJKI-HNNXBMFYSA-N 0.000 description 1
- ZUDHOKVWAFTLCF-NRFANRHFSA-N N#CN(c1c(C[C@@H]2OC(c(cccc3)c3C(O)=O)=O)cccc1)c1c2cccc1 Chemical compound N#CN(c1c(C[C@@H]2OC(c(cccc3)c3C(O)=O)=O)cccc1)c1c2cccc1 ZUDHOKVWAFTLCF-NRFANRHFSA-N 0.000 description 1
- BMPDWHIDQYTSHX-AWEZNQCLSA-N NC(N(c1ccccc1C1)c2ccccc2[C@H]1O)=O Chemical compound NC(N(c1ccccc1C1)c2ccccc2[C@H]1O)=O BMPDWHIDQYTSHX-AWEZNQCLSA-N 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960001922 sodium perborate Drugs 0.000 description 1
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
- C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
- C07D223/28—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a single bond between positions 10 and 11
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
- C07D223/30—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hetero atoms directly attached to the ring nitrogen atom
Definitions
- the present invention relates to a novel process for the preparation of (S)-(+)-10,l l-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxyamide, of formula 2,
- Phthaloylation of nitrile 1 is suitably carried out in inert solvents, e.g. chlorinated solvents such as dichloromethane, chloroform and the like, with an amount of phthalic anhydride ranging from 1 to 1.5 (preferably approx. 1.2) mols compared with nitrile 1, in the presence of a slight molar excess of pyridine (to phthalic anhydride) and of 4-dimethylaminopyridine in catalytic amounts.
- inert solvents e.g. chlorinated solvents such as dichloromethane, chloroform and the like
- the mixture is acidified at a temperature of 10-25 0 C, the organic phase is evaporated off and the phthaloyl derivative 3 is recovered, suspended in a lower alcohol and treated with a substantially equimolar amount of (S)-l-phenylethylamine.
- the solvent is evaporated off and the residue is recrystallized from mixtures of lower chloroalkanes and alicyclic hydrocarbons, e.g. dichloromethane/cyclohexane, to obtain a product consisting of diastereomers 4 and 5 in a 91/9 ratio, which is treated with aqueous alkali.
- (S)-l-Phenylethylamine can be recovered by extraction with a water-immiscible or sparingly water-miscible solvent (e.g. diethyl ether or diisopropyl ether), whereas acidification of the aqueous phase and extraction with a water-immiscible or sparingly water-miscible solvent affords (without isolating intermediate 6) (S)-(+)-5-cyano-10,l l- dihydro-10-hydroxy-5H-dibenz[b,f]azepine 7 of optical purity higher than 90%.
- a water-immiscible or sparingly water-miscible solvent e.g. diethyl ether or diisopropyl ether
- acidification of the aqueous phase and extraction with a water-immiscible or sparingly water-miscible solvent affords (without isolating intermediate 6)
- novel compounds of formulae 3 (and related enantiomers), 4, 5 and 7, are also an object of the present invention.
- Example 3 The product of Example 3 (500 mg, 1.3 mmol), dissolved in EtOH (5 mL), is dropwise added with a 3M K 2 CO 3 solution (5 mL), then with 35% hydrogen peroxide (1.5 ml), at O 0 C. After 30 min. at room temperature, the transformation of nitrile group to amide is completed by heating under reflux, adjusting pH to 14 with few drops of 0.1N NaOH. The reaction mixture is cooled at room temperature for two hours, then concentrated under reduced pressure. The residue is extracted with chloroform (3 x 50 mL) and dried over potassium carbonate. The solvent is evaporated off to afford compound 2 (320 mg, 96% yield), with 95% optical purity (HPLC analysis).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
(S)-(+)-10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxyamide is prepared starting from racemic 5-cyano-10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine by phthaloylation, separation of the diastereomeric salts of the phthaloyl derivative with (S)-phenylethylamine, hydrolysis of the (S, S) salt to (S)-(+)-5-cyano-10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine and hydrolysis of the nitrile group of the latter to amido group, by treatment with peroxy compounds in alkali medium.
Description
A PROCESS FOR THE PREPARATION OF (S)- (+)-10,11-DIHYDRO-IO-HYDROXY-SH-DIBENZ(B^)AZEPINE-S-CARBOXAMIDE
The present invention relates to a novel process for the preparation of (S)-(+)-10,l l-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxyamide, of formula 2,
(2) starting from racemic 5-cyano- 10,11 -dihydro- 10-hydroxy-5H- dibenz[b,f]azepine, of formula 1
(D (S)-(+)- 10,11 -Dihydro- 10-hydroxy-5H-dibenz[b,f]azepine-5- carboxyamide 2 is an intermediate for the synthesis of antiepilectic drugs: see the paper of J. Benes et al. in J. Med. Chem. 1999, 42, 2582-2587 (see also WO 02/096881) which discloses the preparation of said compound 2 by esterification of racemic 10,l l-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5- carboxyamide with mentyloxyacetic acid, separation of the resulting diastereomers and hydrolysis of the respective mentyloxyacetate.
It has now been found that (S)-(+)- 10, 11 -dihydro- 10-hydroxy-5H- dibenz[b,f]azepine-5-carboxyamide 2 can advantageously be prepared starting
from racemic 5-cyano-10,l l-dihydro-10-hydroxy-5H-dibenz[b,f]azepine 1 (disclosed and claimed in EP 1,127,877 and US 6,384,217, both in the Applicant's name), by esterification of compound 1 with phthalic anhydride and transformation of the resulting phthaloyl derivative 3, by salification with (S)-l-phenylethylamine, into diastereomers 4 and 5 which by crystallization afford diastereomer 4 (in marked excess - 10: 1 - compared with 5). From compound 4, by liberation of the phthaloyl derivative 6, (S)-(+)-5-cyano- 10,l l-dihydro-10-hydroxy-5H-dibenz[b,f]azepine 7 is obtained, which can easily be hydrolysed to (S)-(+)-10,l l-dihydro-10-hydroxy-5H- dibenz[b,f]azepine-5-carboxyamide 2 by treatment with peroxides in alkali medium, according to Italian Patent application N. MI2004A002230 in the Applicant's name. The process of the present invention affords, inter alia, the important advantage of making use of the intermediate (S)-I- phenylethylamine which is of common use and at least ten times less expensive than mentyloxyacetic acid used in the known technique. This process is summarized in the following scheme:
Phthaloylation of nitrile 1 is suitably carried out in inert solvents, e.g. chlorinated solvents such as dichloromethane, chloroform and the like, with an amount of phthalic anhydride ranging from 1 to 1.5 (preferably approx. 1.2) mols compared with nitrile 1, in the presence of a slight molar excess of pyridine (to phthalic anhydride) and of 4-dimethylaminopyridine in catalytic amounts. After completion of the reaction, the mixture is acidified at a temperature of 10-250C, the organic phase is evaporated off and the phthaloyl derivative 3 is recovered, suspended in a lower alcohol and treated with a substantially equimolar amount of (S)-l-phenylethylamine. The solvent is evaporated off and the residue is recrystallized from mixtures of lower chloroalkanes and alicyclic hydrocarbons, e.g. dichloromethane/cyclohexane,
to obtain a product consisting of diastereomers 4 and 5 in a 91/9 ratio, which is treated with aqueous alkali. (S)-l-Phenylethylamine can be recovered by extraction with a water-immiscible or sparingly water-miscible solvent (e.g. diethyl ether or diisopropyl ether), whereas acidification of the aqueous phase and extraction with a water-immiscible or sparingly water-miscible solvent affords (without isolating intermediate 6) (S)-(+)-5-cyano-10,l l- dihydro-10-hydroxy-5H-dibenz[b,f]azepine 7 of optical purity higher than 90%. The latter, according to the process of Italian Patent application N. MI2004A002230, yields the final carboxyamide 2 with optical purity higher than 95%.
The novel compounds of formulae 3 (and related enantiomers), 4, 5 and 7, are also an object of the present invention.
The following examples illustrate the process according to the invention. EXAMPLE 1: Preparation of 5-cyano-10,ll-dihydro-10-hydroxy-
5H-dibenz[b,f]azepine phthalic ester
33.5 g of phthalic anhydride in 500 ml of methylene chloride are added with 47 g of 5-cyano- 10,11 -dihydro-10-hydroxy-5H-dibenz[b,f]azepine 1, 1 g 4-dimethylaminopyridine and 17.5 g of pyridine. The reaction is slightly exothermic (temperature raises from 150C to 19°C). The mixture is kept at 30-350C for one hour, cooled to 15°C and added with 100 ml of 2.5M hydrochloric acid. The organic phase is washed with 50 ml of water and then evaporated under vacuum to obtain 75 g of 5-cyano-10-hydroxy-10,l l- dihydro-5H-dibenz[b,f]azepine phthalic ester 3, m.p. 169-1710C. EXAMPLE 2: Preparation of (S)-l-phenylethylamine diastereomeric salts
A suspension of 5 g of 5-cyano- 10,11 -dihydro-10-hydroxy-5H-dibenz- [b,f]azepine phthalic ester 3 in 55 ml of MeOH is very slowly added drop by
drop with a solution of 1.58 g of (S)- 1 -phenylethylamine in 5 ml of MeOH. The solution remains homogeneous during the addition. After keeping at room temperature for 30 min., the solvent is evaporated off under reduced pressure thereby obtaining 7.0 g of a white solid, which is dissolved in 40 ml of CH2Cl2, then added with 50 ml of cyclohexane. After standing overnight, the resulting crystal is filtered and washed with cyclohexane to afford 2.4 g of a white crystalline product, consisting of a mixture of the two diastereomers 4 and 5 in a 91/9 (S,S)/(S,R) ratio (HPLC analysis).
EXAMPLE 3: (S)-(+)-5-Cyano-10,ll-dihydro-10-hydroxy-5H- dibenz[b,f]azepine (7)
2.4 g of the salt of Example 2, dissolved in water (20 ml), are added at room temperature with 0.19 g of NaOH dissolved in 5 ml Of H2O. The mixture is left under stirring for 30-45 min. The resulting solution is extracted with ethyl ether (3 x 10 ml) to remove phenylethylamine (72% recovery). The aqueous basic phase is acidified with dil. HCl to acid pH of approx. 3-4 (turns cloudy) then extracted with CHCI3 for 3 times, dried and concentrated, to obtain 1.8 g of product (100% yield) free from amine, consisting of (S)-(+)-5- cyano-10,l l-dihydro-10-hydroxy-5H-dibenz[b,fJazepine 7, with 91% optical purity, by HPLC analysis. EXAMPLE 4: (S)-(+)-10,ll-Dihydro-10-hydroxy-5h-dibenz[b,f,]- azepine-5-carboxyamide (2)
A mixture of the product of Example 3 (267 mg, 0.69 mmol) dissolved in EtOH (10 ml) and H2O (5 ml) is added with sodium perborate (427 mg, 2.78 mmol), left at room temperature for 12 h, then added with a further 215 mg of perborate and re fluxed for 15 h. pH is adjusted to 14 with a few drops of 0.1N NaOH and the mixture is left to stand in the warmth for 30 min. Part of the ethanol is removed under reduced pressure and the aqueous residue is extracted with ethyl acetate, dried and concentrated. The resulting white
solid is dissolved in methanol, treated with a few ml of hexane, then concentrated to afford 129 mg (72%) of (S)(+)- 10,11 -dihydro-10-hydroxy-5H- dibenz[b,f,]azepine-5-carboxyamide 2, with 95% optical purity.
EXAMPLE 5: (S)-(+)-10,ll-dihydro-10-hydroxy-5H-dibenz[b,f,]- azepine-5-carboxyamide (2)
The product of Example 3 (500 mg, 1.3 mmol), dissolved in EtOH (5 mL), is dropwise added with a 3M K2CO3 solution (5 mL), then with 35% hydrogen peroxide (1.5 ml), at O0C. After 30 min. at room temperature, the transformation of nitrile group to amide is completed by heating under reflux, adjusting pH to 14 with few drops of 0.1N NaOH. The reaction mixture is cooled at room temperature for two hours, then concentrated under reduced pressure. The residue is extracted with chloroform (3 x 50 mL) and dried over potassium carbonate. The solvent is evaporated off to afford compound 2 (320 mg, 96% yield), with 95% optical purity (HPLC analysis).
Claims
1. A process for the preparation of (S)-(+)- 10,11 -dihydro- 10-hydroxy-5H- dibenz[b,f,]azepine-5-carboxyamide of formula 2
(2) characterized in that the nitrile group of (S)-(+)-5-cyano-l 0,11 -dihydro- 10- hydroxy-5H-dibenz[b,f]azepine of formula 7
2. A process as claimed in claim 1, characterized in that (S)-(+)-5-cyano- 10,11 -dihydro- 10-hydroxy-5H-dibenz[b,f]azepine of formula 7 is in turn prepared starting from racemic 5-cyano-10,l l-dihydro-10-hydroxy-5H- dibenz[b,f]azepine of formula 1 by phthaloylation, salification of the phthaloyl derivative of formula 3 with (S)-l-phenylethylamine, separation of the resulting diastereomeric salts 4 and 5 and hydrolysis of the salt 4, according to the following scheme: 
(6) (7) (2)
3. A process as claimed in claim 2, characterized in that the diastereomeric salts 4 and 5 are separated by crystallization from mixtures of lower chloroalkanes and alicyclic hydrocarbons, preferably dichloromethane/cyclohexane .
4. As a novel compound, a compound selected from the group consisting of:
5-cyano- 10,11 -dihydro- 10-(2-carboxy)benzoyloxy-5H- dibenz[b,f]azepine of formula 3 and the related enantiomers; S-1-phenylethylamine S, S and S5R salts with 5-cyano- 10,11-dihydro- 10-(2-carboxy)benzoyloxy-5H-dibenz[b,fjazepine, of formulae 4 and 5; (S)-(+)-5-cyano- 10, 11 -dihydro- 10-hydroxy-5H-dibenz[b,f]azepine of formula 7.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05819292A EP1833798B1 (en) | 2004-11-26 | 2005-11-15 | A process for the preparation of (s)-(+)-10,11-dihydro-10-hydroxy-5h-dibenz[b,f]azepine-5-carboxamide |
| US11/791,582 US7858780B2 (en) | 2004-11-26 | 2005-11-15 | Process for the preparation of (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz (b,f)azepine-5-carboxamide |
| DE602005017073T DE602005017073D1 (en) | 2004-11-26 | 2005-11-15 | PROCESS FOR PREPARING S) - (+) - 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZENE, FAZAZEPINE-5-CARBOXAMIDE |
| CA2589147A CA2589147C (en) | 2004-11-26 | 2005-11-15 | A process for the preparation of (s)-(+)-10,11-dihydro-10-hydroxy-5h-dibenz (b,f) azepine-5-carboxyamide |
| AT05819292T ATE444954T1 (en) | 2004-11-26 | 2005-11-15 | METHOD FOR PRODUCING S)-(+)-10,11-DIHYDRO-10-HYDROXY-5H-DIBENZÄB,FUAZEPINE-5-CARBOXAMIDE |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2004A002291 | 2004-11-26 | ||
| IT002291A ITMI20042291A1 (en) | 2004-11-26 | 2004-11-26 | PROCEDURE FOR THE PREPARATION OF -S-PIU-10,11-DIIDRO-10-HYDROXY-5H-DIBENZ-B, F-AZEPIN-5-CARBOSSIAMMIDE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2006056339A1 true WO2006056339A1 (en) | 2006-06-01 |
Family
ID=36084359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2005/012205 WO2006056339A1 (en) | 2004-11-26 | 2005-11-15 | A process for the preparation of (s)-(+)-10,11-dihydro-10-hydroxy-5h-dibenz (b,f) azepine-5-carboxyamide |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7858780B2 (en) |
| EP (1) | EP1833798B1 (en) |
| AT (1) | ATE444954T1 (en) |
| CA (1) | CA2589147C (en) |
| CY (1) | CY1110526T1 (en) |
| DE (1) | DE602005017073D1 (en) |
| ES (1) | ES2331320T3 (en) |
| IT (1) | ITMI20042291A1 (en) |
| PT (1) | PT1833798E (en) |
| WO (1) | WO2006056339A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011045648A3 (en) * | 2009-10-12 | 2011-06-09 | Matrix Laboratories Limited | Process for preparing (s)-(-)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide and its esters thereof |
| WO2012156987A2 (en) * | 2011-05-19 | 2012-11-22 | Glenmark Generics Limited | A novel process for the preparation of eslicarbazepine |
| WO2014049550A1 (en) | 2012-09-26 | 2014-04-03 | Ranbaxy Laboratories Limited | Process for the preparation of oxcarbazepine and its use as intermediate in the preparation of eslicarbazepine acetate |
| EP3064490A1 (en) | 2015-03-06 | 2016-09-07 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Improved process for the preparation of eslicarbazepine and eslicarbazepine acetate |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9346760B2 (en) | 2011-03-08 | 2016-05-24 | Jubilant Life Sciences Limited | Process for the preparation of (S)-(+)- or (R)-(-)-10-hydroxy dihydrodibenz[B,F]azepines by enantioselective reduction of 10,11-dihydro-10-OXO-5H-dibenz[B,F]azepines and polymorphs thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1127877A2 (en) * | 2000-02-25 | 2001-08-29 | FARCHEMIA S.r.l. | 5-Cyano-10-hydroxy-10,11-dihydro-5H-dibenz[b,f]azepine, processes for its preparation and for its conversion into 5-carbamoyl-10-oxo-10,11-dihydro-5H-dibenz[b,f]azepine or into 5-carbamoyl-5H-dibenz[b,f]azepine |
| WO2002096881A1 (en) * | 2001-05-25 | 2002-12-05 | Portela & Ca Sa | Method for preparation of 10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and 10,11-dihydro-10-0x0-5h-dibenz/b,f/azepine-5-carboxamide |
-
2004
- 2004-11-26 IT IT002291A patent/ITMI20042291A1/en unknown
-
2005
- 2005-11-15 ES ES05819292T patent/ES2331320T3/en active Active
- 2005-11-15 EP EP05819292A patent/EP1833798B1/en not_active Not-in-force
- 2005-11-15 DE DE602005017073T patent/DE602005017073D1/en not_active Expired - Fee Related
- 2005-11-15 PT PT05819292T patent/PT1833798E/en unknown
- 2005-11-15 CA CA2589147A patent/CA2589147C/en not_active Expired - Fee Related
- 2005-11-15 US US11/791,582 patent/US7858780B2/en not_active Expired - Fee Related
- 2005-11-15 AT AT05819292T patent/ATE444954T1/en not_active IP Right Cessation
- 2005-11-15 WO PCT/EP2005/012205 patent/WO2006056339A1/en active Application Filing
-
2009
- 2009-10-30 CY CY20091101130T patent/CY1110526T1/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1127877A2 (en) * | 2000-02-25 | 2001-08-29 | FARCHEMIA S.r.l. | 5-Cyano-10-hydroxy-10,11-dihydro-5H-dibenz[b,f]azepine, processes for its preparation and for its conversion into 5-carbamoyl-10-oxo-10,11-dihydro-5H-dibenz[b,f]azepine or into 5-carbamoyl-5H-dibenz[b,f]azepine |
| WO2002096881A1 (en) * | 2001-05-25 | 2002-12-05 | Portela & Ca Sa | Method for preparation of 10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and 10,11-dihydro-10-0x0-5h-dibenz/b,f/azepine-5-carboxamide |
Non-Patent Citations (2)
| Title |
|---|
| D. KIKELJ ET AL., SYNTH. COMMUN., vol. 14, no. 6, 1984, pages 547 - 556 * |
| DATABASE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften; XP002374960, Database accession no. 3620473,3620675 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011045648A3 (en) * | 2009-10-12 | 2011-06-09 | Matrix Laboratories Limited | Process for preparing (s)-(-)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide and its esters thereof |
| WO2012156987A2 (en) * | 2011-05-19 | 2012-11-22 | Glenmark Generics Limited | A novel process for the preparation of eslicarbazepine |
| WO2012156987A3 (en) * | 2011-05-19 | 2013-03-21 | Glenmark Generics Limited | Novel process for preparation of eslicarbazepine |
| WO2014049550A1 (en) | 2012-09-26 | 2014-04-03 | Ranbaxy Laboratories Limited | Process for the preparation of oxcarbazepine and its use as intermediate in the preparation of eslicarbazepine acetate |
| EP3064490A1 (en) | 2015-03-06 | 2016-09-07 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Improved process for the preparation of eslicarbazepine and eslicarbazepine acetate |
| WO2016142164A1 (en) | 2015-03-06 | 2016-09-15 | F.I.S. - Fabbrica Italiana Sintetici S.P.A. | Improved process for the preparation of eslicarbazepine and eslicarbazepine acetate |
| US9845293B2 (en) | 2015-03-06 | 2017-12-19 | F.I.S.—Fabbrica Italiana Sintetici S.p.A. | Process for the preparation of eslicarbazepine and eslicarbazepine acetate |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2589147A1 (en) | 2006-06-01 |
| ES2331320T3 (en) | 2009-12-29 |
| CA2589147C (en) | 2013-11-05 |
| ATE444954T1 (en) | 2009-10-15 |
| CY1110526T1 (en) | 2015-04-29 |
| US20090105472A1 (en) | 2009-04-23 |
| DE602005017073D1 (en) | 2009-11-19 |
| PT1833798E (en) | 2009-10-28 |
| EP1833798A1 (en) | 2007-09-19 |
| EP1833798B1 (en) | 2009-10-07 |
| US7858780B2 (en) | 2010-12-28 |
| ITMI20042291A1 (en) | 2005-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007000575A (en) | Method for chiral inversion of (s)-(+)- and (r)-(-)-10, 11-dihydro-10- hydroxy-5h -dibenz/b, f/azepine-5 -carboxamide and optically enriched mixtures thereof. | |
| EP1833798B1 (en) | A process for the preparation of (s)-(+)-10,11-dihydro-10-hydroxy-5h-dibenz[b,f]azepine-5-carboxamide | |
| PL213299B1 (en) | Method for preparation of (s)-(+)- and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide | |
| JP4859322B2 (en) | Dibenzo (b, f) azepine derivative and process for producing the same | |
| JP2006525985A (en) | Racemic of (S)-(+)-, and (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz / b, f / azepine-5-carboxamide, and optically concentrated mixtures thereof Method | |
| US20110269962A1 (en) | Process for preparing statins | |
| US7875730B2 (en) | Process for manufacture of racemic Carvedilol | |
| US6548665B2 (en) | Asymmetric synthesis of a key intermediate for making benazepril and analogues thereof | |
| ES2354221T3 (en) | METHOD OF OPTICAL RESOLUTION OF AMLODIPINA. | |
| JP4491412B2 (en) | Method for synthesizing L-γ-methyleneglutamic acid and its analogs | |
| US7078532B2 (en) | Process for manufacture of fosinopril sodium | |
| WO2005030713A2 (en) | Resolution of a narwedine amide derivative | |
| FI88723B (en) | / 2,5-DIHYDRO-2-OXO-5-PHENYL-3-FURANYL / AMINER SAMT DERAS ANVAENDNING VID FRAMSTAELLNING AV ACE-INHIBITORER | |
| EP0370366A2 (en) | Resolution process for benzazepine intermediates | |
| KR100755151B1 (en) | New Process | |
| KR100319030B1 (en) | Process for the preparation of 4-amino-5-hexenoic acid | |
| KR20090053058A (en) | New chiral resolving agents and method for isolating chiral isomer using same | |
| ITMI20110397A1 (en) | PROCEDURE FOR THE PREPARATION OF PYAVASTATIN AND ANALOGUES | |
| JP2004503539A (en) | Separation of Enantiomers of Piperidone Derivatives with In Situ Simultaneous Racemization of Undesired Enantiomers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2589147 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2005819292 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWP | Wipo information: published in national office |
Ref document number: 2005819292 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 11791582 Country of ref document: US |